retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Research Guide: What the Trial Data Reported (2026) Retatrutide for Obesity: Phase 2

Collectively, resistance to PD-1/PD-L1 blockade in NSCLC arises from multifactorial and interrelated processes involving both tumor-intrinsic and microenvironmental components

And that in some cases of A DHD like that neuroinflammation can really get amped up and hijack the brain

Others have loftier ambitions: They hope to harness the drugs powerful effects to achieve better health and longer lives without losing a lot of weight or experiencing side effects such as GI issues and muscle loss

This helps patients consume fewer calories and achieve weight loss

This might be for a brand-name GLP-1 like Ozempic or Wegovy, or a compounded version if your insurance doesnt cover the brand

They can't join if they've had recent significant weight changes, certain surgeries or acute cardiovascular events, use of weight loss drugs within the last 90 days, Type 1 diabetes, or specific hereditary cancer syndromes